Alhusban, A., Al-Azayzih, A., Goc, A., Gao, F., Fagan, S. C., & Somanath, P. R. (2014). Clinically Relevant Doses of Candesartan Inhibit Growth of Prostate Tumor Xenografts In Vivo through Modulation of Tumor Angiogenesis. The American Society for Pharmacology and Experimental Therapeutics.

Alhusban, Ahmed, Ahmad Al-Azayzih, Anna Goc, Fei Gao, Susan C. Fagan, and Payaningal R. Somanath. Clinically Relevant Doses of Candesartan Inhibit Growth of Prostate Tumor Xenografts In Vivo Through Modulation of Tumor Angiogenesis. The American Society for Pharmacology and Experimental Therapeutics, 2014.

Alhusban, Ahmed, et al. Clinically Relevant Doses of Candesartan Inhibit Growth of Prostate Tumor Xenografts In Vivo Through Modulation of Tumor Angiogenesis. The American Society for Pharmacology and Experimental Therapeutics, 2014.